Clinical trials
catalyst calendar across sponsors →Studies where SYRE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional
Held by 14 tracked-famous managers (Holocene Advisors, LP, MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, Balyasny Asset Management L.P., Squarepoint Ops LLC, +9 more) · FINRA short interest 13.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 11 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBDNCT07652294Percentage of participants who experienced an adverse eventNon-randomized · Triple-masked · Treatment | Phase 2 | Enrolling by invitation | Drug: SPY001, SPY002, SPY003 | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | 645 | 2029-03-02 | in 926 d | 2026-08-18 |
| A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)NCT07766005Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Randomized · Quadruple-masked · Treatment | Phase 2 | Not yet recruiting | Drug: SPY072, Placebo, bimekizumab | Hidradenitis Suppurativa (HS) | 150 | Oct 2027 | ≤ 438 d | 2026-08-14 |
| A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisNCT07012395Part A: Change in Robarts Histopathology Index (RHI)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: SPY001, SPY002, SPY003 · Other: Placebo | Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative | 645 | Jun 2027 | ≤ 315 d | 2026-07-28 |
| A Study of SPY003-207 in Healthy VolunteersNCT06873724Treatment emergent adverse eventsRandomized · Quadruple-masked · Basic science | Phase 1 | Active, not recruiting | Drug: SPY003-207 · Other: Placebo | Healthy | 59 | 2026-11-18 | in 91 d | 2026-03-20 |
| A Study of SPY072 in Rheumatic DiseaseNCT07148414Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: SPY002-072, Placebo | Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease | 285 | 2026-10-31 | in 73 d | 2026-06-05 |
| A Study of SPY002-091 in Healthy VolunteersNCT06672718Treatment emergent adverse eventsRandomized · Quadruple-masked · Basic science | Phase 1 | Active, not recruiting | Drug: SPY002-091 · Other: Placebo | Healthy | 50 | 2026-08-19 | today | 2026-06-12 |
| A Study of SPY002-072 in Healthy VolunteersNCT06622070Treatment emergent adverse eventsRandomized · Quadruple-masked · Basic science | Phase 1 | Recruiting | Drug: SPY002-072 · Other: Placebo | Healthy | 56 | 2026-04-03 | — | 2024-11-27 |
| A Study of SPY001-001 in Healthy VolunteersNCT06448247Treatment emergent adverse eventsRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: SPY001-001 · Other: Placebo | Healthy | 96 | 2026-03-10actual | — | 2026-03-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19